Filing Flows › Companies › Ionis Pharmaceuticals › Analysis traps
Ionis Pharmaceuticals (IONS): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q2 2026, to Jun 30, 2026, filed Jul 29, 2026; rules v1.1
Ionis Pharmaceuticals (IONS): 3 rules of 10 triggered on the filings to Jun 30, 2026: stock compensation added back = no economic cost; adjusted profit = economic profit; FCF growth = the business improved; 2 with insufficient data; 4 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
Stock compensation added back = no economic cost Triggered · severity high · confidence high
Stock compensation was $134M, 14.2% of revenue, in FY2025; buybacks were $0 (0.0× the SBC) and the diluted share count still rose 7.0%. 'Adjusted' figures that add SBC back treat pay in shares as free; the cost is borne by every shareholder as dilution, or by the cash spent to buy the shares back.
Innocent reading: A young company paying in equity while it scales; intensity falls as revenue grows.
Adjusted profit = economic profit Triggered · severity high · confidence low
Adjusted EPS was at least 10% above GAAP in 4 of the last 4 quarters (on average 50% above). Costs excluded every quarter (restructuring, stock compensation, amortisation of acquired intangibles, litigation) are a recurring cost of the business, not a one-off.
Innocent reading: A genuine one-off this year (an impairment, a settlement) that happens to span several quarters.
FCF growth = the business improved Triggered · severity medium · confidence medium
Free cash flow rose $226M, from −$546M to −$320M, but working capital released $113M more cash than the year before: 50% of the increase came from sources that need not repeat. Operating cash flow before working capital rose by $119M.
Innocent reading: An expansion programme finished, so capex fell back to maintenance levels for good.
Every rule
A01 FCF growth = the business improved Triggered severity medium · confidence medium
Free cash flow rose $226M, from −$546M to −$320M, but working capital released $113M more cash than the year before: 50% of the increase came from sources that need not repeat. Operating cash flow before working capital rose by $119M.
The figures and how they are read
| Fiscal year before | FY2024 |
| Fiscal year | FY2025 |
| Operating cash flow, year before | −$501M |
| Operating cash flow | −$269M |
| Capex, year before | $45M |
| Capex | $51M |
| Free cash flow, year before | −$546M |
| Free cash flow | −$320M |
| Change in FCF | $226M |
| Change in capex | $6M |
| Working capital: change in its cash contribution | $113M |
| Of which: capex cut | 0.00 |
| Of which: working capital released | $113M |
| Share of the increase that need not repeat | +50.2% |
| Operating cash flow before working capital: change | 118924000.00 |
FCF = operating cash flow − cash capex; ΔFCF = ΔOCF − ΔCapEx; the working-capital part is the change in the cash-bridge items (receivables, inventory, payables, accruals), with the sign of the cash flow statement
Source: FY2025 (cash flow statement, fiscal year) · FY2024 (cash flow statement, fiscal year before)
What would explain it innocently
- An expansion programme finished, so capex fell back to maintenance levels for good
- Suppliers agreed longer payment terms in a contract
- Inventory was brought down after a glut and will stay down
What to look for in the filing
- Maintenance capex (what it costs to keep the assets working)
- Supplier payment terms and any supply-chain financing
- Management's capex guidance for next year
What would show the trap does not apply
- Next year's FCF holds or rises with capex back at its earlier level and working capital no longer releasing cash
- The 10-K's capex guidance and the segment capex show the cut is a completed programme, not deferral
- The working-capital release matches a disclosed change in terms or a divestiture, not stretched payables or a collection push
Look again: next filing.
A07 Stock compensation added back = no economic cost Triggered severity high · confidence high
Stock compensation was $134M, 14.2% of revenue, in FY2025; buybacks were $0 (0.0× the SBC) and the diluted share count still rose 7.0%. 'Adjusted' figures that add SBC back treat pay in shares as free; the cost is borne by every shareholder as dilution, or by the cash spent to buy the shares back.
The figures and how they are read
| Fiscal year | FY2025 |
| Stock compensation | $134M |
| Revenue | $944M |
| SBC / revenue | +14.2% |
| Buybacks | 0 |
| Buybacks / SBC | 0.0 |
| Diluted shares, year before | 149.5M shares |
| Diluted shares | 160.0M shares |
| Diluted shares: change | +7.0% |
SBC / revenue from the cash flow statement's add-back; the diluted weighted share count year over year; buybacks from the financing section
Source: FY2025 (stock compensation, buybacks and the diluted share count, fiscal year)
What would explain it innocently
- A young company paying in equity while it scales; intensity falls as revenue grows
- Buybacks at prices below intrinsic value make up for the dilution over time
- A one-off grant (an acquisition, a founder award) rather than a steady level
What to look for in the filing
- The share count after the latest buybacks (the next 10-Q's cover)
- The price paid for the buybacks against the shares' value
- Unvested awards outstanding
What would show the trap does not apply
- The diluted share count falls over two years with buybacks at least equal to the stock compensation
- Stock compensation falls as a share of revenue in each of the next two years
Look again: next filing.
B02 Receivables growing = future cash is certain Insufficient data
fewer than five quarters with receivables and revenue on file (a year-over-year comparison needs five)
B08 Adjusted profit = economic profit Triggered severity high · confidence low
Adjusted EPS was at least 10% above GAAP in 4 of the last 4 quarters (on average 50% above). Costs excluded every quarter (restructuring, stock compensation, amortisation of acquired intangibles, litigation) are a recurring cost of the business, not a one-off.
The figures and how they are read
| Quarter / adjusted EPS / GAAP EPS / gap | 2025-09-30 / -0.6125 / -0.8 / 0.306; 2025-12-31 / -1.1481 / -1.41 / 0.228; 2026-03-31 / -0.30303 / -0.56 / 0.848; 2026-06-30 / -0.4242 / -0.69 / 0.627 |
| Quarters with adjusted ≥ 10% above GAAP | 4 |
| Quarters compared | 4 |
| Latest gap | +62.7% |
the analysts' 'actual' (usually the company's adjusted EPS) against GAAP net income ÷ diluted shares for the matching quarter; a gap of 10% or more counts (the stand-in until three releases' reconciliation tables are on file)
Source: 2025-09-30 (adjusted -0.61 vs GAAP -0.80) · 2025-12-31 (adjusted -1.15 vs GAAP -1.41) · 2026-03-31 (adjusted -0.30 vs GAAP -0.56) · 2026-06-30 (adjusted -0.42 vs GAAP -0.69)
What would explain it innocently
- A genuine one-off this year (an impairment, a settlement) that happens to span several quarters
- Amortisation of acquired intangibles, which many investors also exclude by choice
- The analysts' 'actual' is not the company's own adjusted figure
What to look for in the filing
- The reconciliation table in the earnings release: which items, how much, how often
- Whether the same items were excluded in earlier years
What would show the trap does not apply
- The reconciliation shows the excluded items ending (a restructuring with its final charge, a settlement paid) and the gap to GAAP closes in the next quarters
- The excluded items are only amortisation of acquired intangibles and the cash paid for the deals is in the investing cash flow
Look again: next filing.
C02 Low net debt = no refinancing risk Not triggered confidence medium
$443M comes due within a year, 4.6× covered by cash and investments of $2.1B.
The figures and how they are read
| Cash and investments | $2.1B |
| Debt | $1.8B |
| Net debt | −$242M |
| Due within a year | $443M |
| Read from | the debt maturity table |
| Free cash flow, twelve months | −$561M |
| Cash plus free cash flow | $2.1B |
| Coverage of what is due | 4.6 |
| Due in the second year | $19M |
| Balance sheet date | 2026-06-30 |
due within a year from the maturity table (else the current portion of debt), against cash and investments plus free cash flow over the last twelve months (zero if negative); no credit lines assumed
Source: FY2025 (debt maturities, cash and investments)
D03 EPS growth = profit growth Not applicable
a loss in one of the quarters: EPS growth has no meaning
E02 Low P/E at a cyclical peak = undervalued Not applicable
a loss on a trailing or mid-cycle basis: the P/E has no meaning
E07 A precise DCF value = the true value Insufficient data
no DCF in the valuation research for this company
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → Ionis Pharmaceuticals: cash flow → Earnings quality score →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.